Amantadine hydrochloride for the treatment of traumatic brain injury
US12396964B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 26, 2022 |
| Grant date | Aug 26, 2025 |
| Priority date | — |
| Expiry date | Oct 26, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is a dosing regimen for administering an aqueous composition of amantadine hydrochloride to a patient having a traumatic brain injury. The dosing regimen includes administering a first dose and a second dose of amantadine hydrochloride by intravenous injection. The first dose comprises between 100-200 mg of amantadine hydrochloride in an aqueous solution of about 200-300 ml over a period of about two to about four hours. The second dose comprises between 100-200 mg of amantadine hydrochloride in an aqueous solution of about 200-300 ml over a period of about two to about four hours. The second dose is administered after about four to six hours after the first dose is fully administered.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.